Results 21 to 30 of about 12,025 (204)
Corrigendum to "Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium". [PDF]
Biomed Res Int, 2019 [This corrects the article DOI: 10.1155/2018/7473690.].
Hamelmann E.
europepmc +3 more sources
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? [PDF]
European Respiratory Review, 2016 Asthma is a chronic inflammatory disorder of the airways that is a major global burden on both individuals and healthcare systems. Despite guideline-directed treatment, a significant proportion of patients with asthma do not achieve control. This review focuses on the potential use of long-acting anticholinergics as bronchodilators in the treatment of ...
Busse, William W +3 more
openaire +3 more sources
Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases [PDF]
Therapeutic Advances in Chronic Disease, 2014 Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.
Khuder, Alagha +9 more
openaire +2 more sources
Emerging role of long acting muscarinic antagonists for asthma [PDF]
British Journal of Clinical Pharmacology, 2013 Acetlycholine is involved in the control of airway smooth muscle constriction and in recruitment of inflammatory cells via neuronal and paracrine effects on muscarinic type 3 receptors. Long acting muscarinic antagonists (LAMA) are well established in guidelines for COPD but are not currently licensed for use in asthma. There are emerging data from key
openaire +3 more sources
Data in Brief, 2019 This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained.
James Donohue +8 more
doaj +1 more source
Issues on Safety of Long-Acting Muscarinic Antagonist
Tuberculosis and Respiratory Diseases, 2011 The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result.
Yang Deok Lee, Yongseon Cho, Min Soo Han
openaire +1 more source
Journal of Clinical and Biomedical Sciences, 2018 Revefenacin, a long-acting muscarinic receptor antagonist was approved by US Food and Drug Administration in November 2018 for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
Bhuvana K
doaj +1 more source
Respiratory Research, 2017 Background Methacholine dose-response curves illustrate pharmacologic bronchoprotection against methacholine-induced airway hyperresponsiveness and can be used to quantitate changes in airway sensitivity (position), reactivity (slope), and maximal ...
Christianne M. Blais +2 more
doaj +1 more source
Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER
Clinical and Translational Allergy, 2022 Background In asthma, persistent airflow limitation (PAL) is associated with poorer control, lung function decline and exacerbations. Using post‐hoc analyses we evaluated: the relationship between post‐salbutamol PAL at screening, airflow limitation (AL)
Alberto Papi +5 more
doaj +1 more source
Respiratory Research, 2017 Background Muscarinic-receptor antagonists and β-adrenoceptor agonists are used, alone or in combination, as first-line treatment for chronic obstructive pulmonary disease.
Michele Baroffio +2 more
doaj +1 more source